Jolt to Serum Institute as govt panel says no to Covovax trial on children | Latest News India - Hindustan Times
close_game
close_game

Jolt to Serum Institute as govt panel says no to Covovax trial on children

By | Written by Amit Chaturvedi, Hindustan Times, New Delhi
Jul 01, 2021 07:01 AM IST

The clinical trials of Covovax began in India in March. But the Subject Expert Committee of the Central Drugs Standard Control Organisation denied the approval for its trial on children noting that the vaccine has not been approved in any country.

An expert panel of the country's central drug authority on Wednesday recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years, News agency PTI reported.

Covovax is being produced by Serum Institute of India.(HT Photo)
Covovax is being produced by Serum Institute of India.(HT Photo)

The SII had applied to the Drugs Controller General of India (DCGI) on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.

Hindustan Times - your fastest source for breaking news! Read now.

But the the Subject Expert Committee of the Central Drugs Standard Control Organisation denied the permission saying Covovax has not been approved in any country, according to PTI. The SII has been asked to submit the safety and immunogenicity data (of Covovax) from the ongoing clinical trial in adults before proceeding with the trials on children, PTI reported.

Novavax had announced last month that NVX-CoV2373 demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.

If approved, Covovax would have been the third vaccine to be tested on children in the country after Bharat Biotech’s Covaxin and Zydus Cadilla’s ZyCov-D.

The Pune-based company has tied up with US biotechnology company Novavax to locally manufacture NVX-CoV2373 under the brand name Covovax.

The clinical trials of Covovax began in India in March and SII chief executive officer (CEO) Adar Poonawalla had earlier said the vaccine could be launched in India by September for adults.

“Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia!” he later said in a post on Twitter.

So far, four vaccines - Bharat Biotech’s Covaxin, the SII’s Covishield, Russia’s Sputnik V and the one manufactured by Moderna (sold unde the brand name 'Spikevax' int he US) - have been cleared by the Indian government.

The SII had rolled out Covishield vaccine in the country in January. It had entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On